Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 October 2014Website:
http://www.corbuspharma.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:30:43 GMTDividend
Analysts recommendations
Institutional Ownership
CRBP Latest News
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA.
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.
Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events.
Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow.
NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.
Small-cap stocks have historically shown better performance compared to larger stocks. After a period of lagging performance, it seemed like small-cap stocks were poised to make a comeback.
What type of business is Corbus Pharmaceuticals Holdings?
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
What sector is Corbus Pharmaceuticals Holdings in?
Corbus Pharmaceuticals Holdings is in the Healthcare sector
What industry is Corbus Pharmaceuticals Holdings in?
Corbus Pharmaceuticals Holdings is in the Biotechnology industry
What country is Corbus Pharmaceuticals Holdings from?
Corbus Pharmaceuticals Holdings is headquartered in United States
When did Corbus Pharmaceuticals Holdings go public?
Corbus Pharmaceuticals Holdings initial public offering (IPO) was on 27 October 2014
What is Corbus Pharmaceuticals Holdings website?
https://www.corbuspharma.com
Is Corbus Pharmaceuticals Holdings in the S&P 500?
No, Corbus Pharmaceuticals Holdings is not included in the S&P 500 index
Is Corbus Pharmaceuticals Holdings in the NASDAQ 100?
No, Corbus Pharmaceuticals Holdings is not included in the NASDAQ 100 index
Is Corbus Pharmaceuticals Holdings in the Dow Jones?
No, Corbus Pharmaceuticals Holdings is not included in the Dow Jones index
When was Corbus Pharmaceuticals Holdings the previous earnings report?
No data
When does Corbus Pharmaceuticals Holdings earnings report?
The next expected earnings date for Corbus Pharmaceuticals Holdings is 07 November 2024